Introduction {#S5}
============

Multiple sclerosis (MS) is an autoimmune disease characterized by multiple lesions with plaques in the brain and spinal cord. The disease is associated with an inflammatory process that attacks and destroys the myelin sheaths around axons in the brain and spinal cord. The cause of MS is unknown, although the disease is thought to be triggered by environmental factors operating on a predisposing genetic background. Genome-wide association studies (GWAS) have identified numerous susceptibility loci, mainly associated with immunological processes \[[@R1]\]. The human leukocyte antigen (HLA) immune gene-cluster, particularly HLA-DRB1\*1501, is the main genetic risk factor for the disease \[[@R2],[@R3]\].

There has been much speculation that an infectious agent may contribute to MS. Based on the epidemiology of MS, including geographic patterns, isolated outbreaks and migration studies, viruses have long been suspected as causative agents \[[@R4]--[@R6]\]. There is no direct evidence for the involvement of an exogenous retrovirus in MS, but endogenous retroviruses may be an important factor in MS pathogenesis. The possibility that retroviruses play a role in the pathogenesis of MS has been considered since the 1980s, when Perron showed reverse transcriptase (RT) activity and retroviral particles in leptomeningeal cells taken from a patient with MS \[[@R7]--[@R10]\]. Since that time, HERVs have been detected in blood, CSF, and brain tissue from MS patients, as reviewed by Douville RN, Nath A \[[@R11]\]. Human endogenous retroviruses (HERVs) are parts of the human genome, with approximately 98,000 ERV elements and fragments \[[@R12]--[@R14]\]. It is believed that HERVs are remnants of prehistoric exogenous retroviruses, integrated in the human genome during evolution through germ line infection \[[@R15]\]. Several transcripts and proteins of genes from the HERV-W family have been detected in the central nervous system and they have been associated with neuroinflammation \[[@R16]--[@R18]\]. Antibodies reactive with GAG or ENV antigens from HERVs can be detected in human sera with elevated levels in patients with autoimmune disease \[[@R19]\].

Previously we performed RNA-seq on frozen human brain specimens and showed statistically significant expression differences between progressive MS and normal controls for some HERV domains \[[@R20],[@R21]\]. Importantly, detection of this signal required using a bioinformatics approach called "comprehensive mapping" which counts all detectable alignments to a given sequencing read, rather than only the most specific match. Furthermore, aggregating sequencing hits by domains suggested that the expression of GAG (core) and ENV (envelope) domains is associated with the MS disease process. The objective of this study was to quantify the expression of selected HERV GAG and ENV domains in additional frozen, cryo preserved brain samples from MS patients in comparison to normal controls. Here, several qPCR experiments were performed to gain an understanding of the overall expression of HERV GAG and ENV genes, divided into multiple HERV clades.

Materials and Methods {#S6}
=====================

a. Brain specimens {#S7}
------------------

Cryo preserved white matter from MS plaques (N=33) and normal white matter control brain specimens from patients without any brain diseases (N=9) were obtained from the Rocky Mountain MS Center Tissue Bank (Westminster, CO, USA) and the UCLA Human Brain and Spinal Fluid Resource Center (Los Angeles, CA, USA). The MS samples included; chronic progressive MS (CPMS, n=5), primary progressive MS (PPMS, n=4), secondary progressive (SPMS, n=14), relapsing remitting MS (RRMS, n=3). Confirmed MS cases with no clinical subtype (unclassified MS, n=7) were also included in the study for a total of 33 MS samples. These specimens, as well as accompanying clinical and pathologic information ([Table 1](#T1){ref-type="table"}), were de-identified before shipment. The research plan was submitted to the University of Utah Health Sciences Center IRB for review. Since this research involved only de-identified post-mortem material, it was found to be exempt from IRB review and oversight (IRB \#00028658).

b. HERV database and Primer design {#S8}
----------------------------------

The retroviral gene catalog (RVGC) was compiled by aligning the protein domains in the Gypsy 2.0 database with the human genome (NCBI build 37.p13) \[[@R22]\]. The RVGC contains human genomic sequences with detectable protein homology (BLASTX) to entries in GyDB 2.0 domains database: core (GAG), envelope (ENV), reverse transcriptase (RT), integrase (INT) SCAN-A2, KRAB-A, dUTPase, RNase H, protease (AP) and chromo domain (CHR) ([Supplementary Data](#SD1){ref-type="supplementary-material"}). RVCG entries were named with arbitrary unique codes of the form: \<domain type\>\_U\<sequential_integer\> ([Table S1](#SD4){ref-type="supplementary-material"}).

Deep sequencing showed that some HERV domains including GAG and ENV were overexpressed in MS samples \[[@R20],[@R21]\]. Based on these results, the 28 GAG and 88 ENV gene sequences in the RVGC were aligned using Clustal Omega \[[@R23]\]. The direction of each sequence was determined by finding the longest open reading frame of the sequence. Before alignment all domain sequences were rectified to the sense orientation if necessary. GAG and ENV phylogenies were constructed using neighbor-joining ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). The major nodes within the phylogenies were used to define clades within the GAG and ENV domains ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

In order to amplify multiple similar GAG and ENV loci spread across the human genome, primers were designed to be clade-specific, rather than locus specific. For this purpose, clade consensus sequences from the Clustal Omega multiple alignments were used to derive qPCR primer pairs, using Primer3 \[[@R24]\]. These primer pairs were 20--24 bp in length, with annealing temperatures of 58--60°C, with no predicted low-energy self-dimers, predicted to give 100--120bp amplicons. The primer sequences were aligned to the human genome using BLAST to predict possible amplicons \[[@R25]\]. Primers predicted to specifically bind the clade-specific consensus sequence were selected to minimize their hybridization to the other clades. Several primer pairs were designed for each of the GAG and ENV clades. The primer sequences used in the study are specified in [Table 2](#T2){ref-type="table"}.

c. RNA extraction and cDNA synthesis {#S9}
------------------------------------

Study specimens from the frozen blocks were obtained using 6 mm sterile circular skin biopsy punch blades (VWR, Radnor, PA, USA). The tissue specimens (each approximately 100 mg) were homogenized by finely chopping them with a sterile blade in a sterile weigh boat, all on dry ice, before placing them into RNA-lysis buffer. The RNA was extracted using the RN easy Lipid Tissue Mini Kit (Qiagen, **Hilden, Germany** and Germantown, MD, USA) and quantified using an RNA High Sensitivity (HS) Assay Kit (Life Technologies/Thermo Fisher Scientific, Carlsbad, CA, USA) on a Qubit 2.0 Fluorometer instrument (Invitrogen/Thermo Fisher Scientific, Carlsbad, CA, USA). Extracted RNA was DNase treated using a TURBO DNA-free Kit (Life Technologies/Thermo Fisher Scientific, Carlsbad, CA, USA). Nucleic acids in the DNase treated specimens were quantified by using a Qubitds DNA HS Assay Kit. A total of 500 ng of RNA was used for the reverse transcription (RT) reaction using Omniscript RT (Qiagen, Hilden, Germany and Germantown, MD, USA), using random hexamers according to the manufacturer's instructions. The resulting cDNA was aliquoted and stored at −20°C.

Several reference genes, previously used in studies of gene expression in neuronal tissue, were considered for use in this study: ubiquitin C (UBC), RNA polymerase II polypeptide (RP II), ribosomal large subunit protein 19 (RPL19), β-2-microglobulin (B2M), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) \[[@R26],[@R27]\]. RNA expression levels for each of the candidate reference genes were determined by qPCR of the MS and control specimens. The geNorm application was used to determine the best reference gene \[[@R28]\]. RPL19 was selected as the reference gene due to the least variation in expression levels among all the specimens.

Five primer pairs were designed from consensus sequences for each of the 3 GAG and 3 ENV clades, for a total of 30 primer pairs. Melting curves from qPCR reaction were examined to determine suitable primer pairs to carry forward in the study. Specifically, 12 primer pairs demonstrating single homogenous amplification products were used for the study. Standard curves for each primer pair including reference gene candidates are shown in [supporting data](#SD1){ref-type="supplementary-material"}.

d. qPCR and Data analysis {#S10}
-------------------------

Each reaction was run in duplicate with no-template, and no-RT controls. Average Ct value was considered for analysis according to the MIQE guidelines \[[@R29]\]. Control and MS samples (5 µl each) were pooled together and serially diluted 2-fold. This dilution series was used to obtain Ct standard curves for each gene of interest ([Supplementary Data](#SD1){ref-type="supplementary-material"}). Calibration curves with slopes in the range of .95--1.29 and R^2^\<0.95 were considered for analysis. For each plate, PCR amplification efficiency was determined from the standard curve using the equation: PCR efficiency=(2^−1/slope^−1) × 100% ([Supplementary Figures](#SD5){ref-type="supplementary-material"}). Gene expression values were calculated from the standard curve for each control and MS specimen, normalized by RPL19 expression for each sample. The median expression values for each primer pair was derived for the control and MS groups. The expression change (fold change) was derived by dividing the median expression value of the MS group from the median of the control group. The Mann-Whitney U-test was used to detect differences among the groups \[[@R30]\]. We considered the difference to be statistically significant when p\< 0.05.

Results {#S11}
=======

a. Frozen Brain samples {#S12}
-----------------------

Characteristics of the study samples are shown in [Table 1](#T1){ref-type="table"}. Thirty-three MS samples were compared to 9 normal controls. The number of control specimens was lower than MS samples due to limited availability of normal controls from the brain bank sources. The post-mortem interval (PMI), i.e., the time between death and collection of the brain sample, range was 2--39 hours. The PMI was significantly longer in the MS group (μ=17 hrs) than in the controls (μ=9.5 hrs, p=0.0002). Age, sex, and year of collection were not significantly different between the groups.

b. HERV GAG and ENV Phylogenies {#S13}
-------------------------------

[Figure 1](#F1){ref-type="fig"} shows the related GAG sequences classified by phylogeny into three different clades. According to Gypsy database annotation these clades include GAGs which belong to family or subfamily HERV-K10, K-HERV and HERV-E (specified in [Table S1](#SD4){ref-type="supplementary-material"}). Phylogeny using a neighbor joining tree of the ENV sequences also revealed three separate clades ([Figure 2](#F2){ref-type="fig"}). Env sequence of HERV-W family; MSRV/HERV-W (AF331500.1), was also included in the ENV phylogeny \[[@R31]\]. The ENV sequences belonged to families including HERV-K10, K-HERV, HERV-E, Retrovirus-like Element-Isoleucine (RTVL-Ia), Mouse Mammary Tumor Virus (MMTV), and the D-type retrovirus Squirrel Monkey-like Retrovirus (SMRV-H) characterized from human B lymphocytes \[[@R32],[@R33]\] ([Table S1](#SD4){ref-type="supplementary-material"}).

c. Expression analysis {#S14}
----------------------

Twelve clade-specific primer pairs were tested for the GAG and ENV domains. The MSRV-ENV primer sequences were kindly provided by H. Perron \[[@R32]\]. Each primer pair was tested by performing qPCR with on the pooled RNA extractions (from all control and MS samples). *In silico* analysis of these primer pairs was performed using Mega BLAST. This showed a heterogeneous population of predicted amplicons that mapped to multiple different human chromosomal locations specified in [Table S1](#SD4){ref-type="supplementary-material"}.

RPL19 was selected as the reference gene for normalization of expression because it had the lowest expression variation among the samples. Normalized gene expression levels for each of the targeted HERV GAG domains are shown in [Figure 3](#F3){ref-type="fig"}. The data is summarized as relative fold change (log~2~) for each primer pair. Expression of GAG clade 1A, 3B, and 3C were significantly increased while GAG clade 3A was decreased in the MS samples (N=33) compared to controls. The pattern of GAG expression for the MS subtypes among each of the clades was similar to that for the MS group as a whole ([Figure S1](#SD2){ref-type="supplementary-material"}). The magnitude of the significant changes in GAG expression was small with fold-changes only 0.74--1.25.

Expression differences between the MS and control groups among the ENV clades studied were also small, with fold-changes less than 1.5 ([Figure 4](#F4){ref-type="fig"}). No differences were seen in the expression of ENV clade 1. The expression of ENV clade 2 (fold-change 1.33), clades 3A and 3B (fold-change 1.2--1.27), and ENV MSRV/HERV-W (fold-change 1.15) were all increased in the MS group compared to controls. The pattern of ENV expression for the MS subtypes among each of the clades was similar to that for the MS group as a whole ([Figure S2](#SD2){ref-type="supplementary-material"}).

Discussion {#S15}
==========

This study compared HERV GAG and ENV domain expression measured by qPCR in frozen brain tissue specimens collected from individuals with MS compared to neurologically normal controls. While this study showed several significant differences in HERV expression, the magnitude of these differences was relatively small (less than 1.5-fold). These results indicate that the expression of HERV GAG and ENV regions do not differ greatly between different types of MS and controls in these frozen brain samples.

There are approximately 40,000 HERV elements distributed among thirty five human HERV families classified by Repbase \[[@R14],[@R34]\]. Transcriptional activity of representative members of 20 HERV families in several different normal human tissues has been studied by microarray \[[@R34]\]. Our attempts to clone and amplify specific HERV loci of interest from the cDNA derived from these frozen brain samples was not successful, likely due to the highly homologous nature of the HERV sequences we were trying to study (data not shown). For this reason, a more unconventional approach was employed utilizing alignments among related HERVs (clades).

Specifically, this study used an alignment approach, employing HERV phylogenies ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}) to design consensus primer sequences ([Table 2](#T2){ref-type="table"}) amplifying multiple different HERV ENV and GAG regions. These regions, designated as clades and subclades in this study, were derived from 28 GAG and 88 ENV domain sequences distributed among many different HERV families ([Table S1](#SD4){ref-type="supplementary-material"}). The approach we took does not formally exclude the possibility that some very specific HERV loci might very elevated in MS brain tissue. Rather, we were interested in getting a broad overview of HERV expression in MS brain tissue, complementing our previous sequencing data.

HERVs constitute about 8% of the human genome \[[@R35]\]. They are scattered widely throughout the human genome, and most cannot produce virus particles. HERVs have recently been shown to act as tissue-specific enhancers of gene transcription \[[@R36]\], and some human proteins are the result of HERV "domestication." One example is syncytin, an important protein that allows for development of the placenta \[[@R37],[@R38]\]. HERVs have been proposed as etiological cofactors in chronic diseases such as cancer, autoimmune disorders, and neurological disease \[[@R39]\]. Two complete ENV ORFs from the HERV-W family are thought to be associated with MS: MSRV, and ERVWE1 (syncytin-1) \[[@R10]\].

Our group recently reported an RNA-seq study showing that some HERVs and other retro elements are significantly over expressed in a smaller set of frozen MS and control brain tissue samples. That study found over expression of GAG sequences mapping to GAG Clade 1 (HERV-K10, K-HERV) and ENV sequences mapping to ENV clades 2 (RTVL-Ia) and 3 (K-HERV) ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). However, these findings were partially confirmed by the present qPCR study where expression of ENV clades 3A and 3B (HERV-K and HERV-E) were increased in MS. Other groups have reported increased levels of ENV MSRV (HERV-W) in blood, spinal fluid, and brain samples in MS patients \[[@R17]\]. We did confirm that finding here, but the magnitude of the MSRV expression increase was relatively small -- only 1.15 fold-change).

A number of assumptions are inherent to this study. First, HERV GAG and ENV regions were chosen for evaluation because multiple reports show that these are the retrovirus genes most likely to be involved in immunopathogenesis \[[@R17],[@R40]--[@R43]\]. Second, we assume that the collapse of GAG and ENV genes from the Gypsy 2.0 database into the RVGC is sufficiently representative of all GAG and ENV HERV domains. Third, we assume that the primer pairs designed from the HERV GAG and ENV phylogenies and divided into related sequences (clades), providing a reasonable representation of these domains' RNA within the samples. Finally, we assume that these postmortem samples, typically taken several hours after death, accurately reflect the premortem RNA content of the tissue. There is no doubt that cellular RNA is not static after death, and this clearly a limitation of our study, but fresh brain samples from neurologically-normal or diseased people are simply not available for comparison. Our MS samples had significantly longer PMIs than the controls, and this could have decreased the expression measured in the MS group more than in the controls, leading to an underestimation of expression differences between the groups. However, any PMI effect on expression should be canceled by RPL19 normalization which, presumably, deteriorates at a similar rate to the HERV domains we measured. All these assumptions can be criticized, but the goal of the study was to provide a broad view of HERV expression in MS white matter samples.

Conclusion {#S16}
==========

Expression of GAG and ENV mapping to HERV-E, RTVL and HERV-K10 families were significantly increased in the MS group. However, the relative expression differences between the MS and control groups were small, differing less than 1.5-fold. These results indicate that the expression of HERV GAG and ENV regions do not differ greatly between MS and controls in these frozen brain samples. This work only partially confirms the sequencing data previous derived from similar frozen MS brain specimens.

Supplementary Material {#SM}
======================
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![GAG sequence phylogeny-Twenty-eight non redundant GAG sequences were pulled from the RVGC (see Methods). Phylogeny was constructed using a neighbor-joining algorithm from the distance matrix. GAG sequences were classified into three different clades outlined by the boxes. GAG sequences over expressed in MS compared to controls and as determined by RNA-seq are displayed in red font.](nihms900509f1){#F1}

![ENV sequence phylogeny-Eighty-eight non redundant ENV sequences were pulled from the RVGC (see Methods). Phylogeny was constructed using a neighbor-joining algorithm from the distance matrix. ENV sequences were classified into three different clades outlined by the boxes. ENV sequences over expressed in MS compared to controls and as determined by RNA-seq are displayed in red font.](nihms900509f2){#F2}

![GAG domain expression in MS *vs* control-Differences in normalized expression for each primer pair are shown as Log~2~ (MS median/control median). Significance in expression differences was determined using the nonparametric Mann-Whitney test comparing expression values for the MS patients (N=33) to the controls (N=9). p-values for the statistically significant comparisons are shown on the chart.](nihms900509f3){#F3}

![ENV domain expression in MS *vs* control-Differences in normalized expression for each primer pair are shown as Log~2~ (MS median/control median). Significance in expression differences was determined using the nonparametric Mann-Whitney test comparing expression values for the MS patients (N=33) to the controls (N=9). p value for statistically significant groups is mentioned.](nihms900509f4){#F4}

###### 

Characteristics of the frozen brain samples used in this study.

  Group                                  Specimen   PMI   Age   Sex    Collection Year           Clinical History/MS Type            Specimen Location
  -------------------------------------- ---------- ----- ----- ------ ------------------------- ----------------------------------- -------------------
  Normal Controls                        5          2     55    F      1989                      NA                                  cerebrum
  202[\*](#TFN1){ref-type="table-fn"}    4          57    M     1983   post-surgical infection   cerebrum                            
  214[\*](#TFN1){ref-type="table-fn"}    4          56    M     1981   heart disease             cerebrum                            
  3236                                   16         67    M     2002   esophageal cancer         frontal WM                          
  3276[\*](#TFN1){ref-type="table-fn"}   19         54    M     2002   heart disease             frontal WM                          
  33[\*](#TFN1){ref-type="table-fn"}     5          69    M     1983   lung disease              cerebrum                            
  3371[\*](#TFN1){ref-type="table-fn"}   16         52    M     2002   lung cancer               frontal WM                          
  3348[\*](#TFN1){ref-type="table-fn"}   9          76    F     2002   heart disease, diabetes   frontal WM                          
  3540                                   11         68    M     2003   lung cancer               frontal WM                          
  MS                                     159        NA    53    M      1983                      chronic progressive                 WM
  164                                    NA         NA    M     1983   Unclassified              WM                                  
  216                                    5          71    F     2003   Unclassified              WM                                  
  2096                                   NA         NA    M     NA     secondary progressive     periventricular WM                  
  2485[\*](#TFN1){ref-type="table-fn"}   9          69    M     1997   primary progressive       frontal WM                          
  2696[\*](#TFN1){ref-type="table-fn"}   21         86    F     1998   primary progressive       periventricular WM                  
  2742                                   17         60    M     1998   primary progressive       periventricular WM, cerebellum      
  2743                                   23         59    F     1998   secondary progressive     subcortical WM                      
  2758                                   NA         60    M     1999   secondary progressive     periventricular WM                  
  2778                                   39         61    F     1998   secondary progressive     WM, temporal cortex                 
  2800                                   9          64    F     1998   secondary progressive     WM, frontal cortex                  
  2946[\*](#TFN1){ref-type="table-fn"}   NA         59    M     1999   secondary progressive     periventricular WM, parietal lobe   
  2966                                   NA         55    F     2000   secondary progressive     periventricular WM                  
  3010                                   NA         49    F     2000   secondary progressive     frontal WM, frontal lobe            
  3056                                   10         61    M     2000   relapsing remitting       WM, frontal cortex                  
  3093                                   18         68    M     2000   Unclassified              periventricular WM, basal ganglia   
  3161[\*](#TFN1){ref-type="table-fn"}   20         51    F     2001   secondary progressive     WM, frontal-parietal                
  3250                                   17         75    M     2002   secondary progressive     periventricular WM                  
  3289                                   29         54    F     2001   Unclassified              periventricular WM                  
  3413                                   10         38    F     2002   relapsing remitting       periventricular WM                  
  3422                                   12         62    M     2002   relapsing remitting       periventricular WM, cerebellum      
  3474                                   9          70    F     2002   chronic progressive       periventricular WM                  
  3502                                   16         78    M     2003   secondary progressive     periventricular WM,                 
  3509[\*](#TFN1){ref-type="table-fn"}   11         74    F     2003   primary progressive       periventricular WM                  
  3831                                   21         82    F     2004   chronic progressive       occipital WM                        
  3835                                   29         65    M     2004   chronic progressive       periventricular WM                  
  3867                                   13         75    M     2004   secondary progressive     periventricular WM                  
  3891                                   25         53    M     2005   chronic progressive       occipital WM                        
  3894                                   32         71    M     2004   secondary progressive     parietal WM                         
  3928                                   10         53    F     2004   secondary progressive     occipital WM                        
  4201                                   14         75    F     2006   Unclassified              occipital WM                        
  4212                                   19         50    F     2006   Unclassified              frontal WM                          
  4218                                   15         63    F     2006   Unclassified              frontal WM                          

Specimen used in the preceding RNA sequencing study \[[@R21]\].

NA=information not available from the participating brain banks

PMI=post-mortem interval (i.e., time elapsed between death and collection of the tissue specimen), rounded to the nearest hour

###### 

Primers designed for this study.

  Domain     Primer Pair                Forward sequence (5'-3')    Reverse Sequence (5'-3')
  ---------- -------------------------- --------------------------- --------------------------
  GAG        Clade 1A                   GCAACATCTTGGAGCCTTG         ATCTGCCTTAGAGCCTGGGA
  Clade 1B   ATCTTGGAGCCTTGCCACAA       ATCTGCCTTAGAGCCTGGGA        
  Clade 1C   AACATCTTGGAGCCTTGCCA       ATCTGCCTTAGAGCCTGGGA        
  Clade 2    GCCTTCACATATTCTGTAATT      GCAAGGTTGCAAGATGCAGCTC      
  Clade 3A   CAAATGCCCCTGAGAGAGCA       TTCCAGTTGAGAAGGTCGGC        
  Clade 3B   CCACCAGATAACCACACCCC       TGCTCTCTCAGGGGCATTTG        
  Clade 3C   TTAAGAGGACAGGCAGCAGC       GGGGTGTGGTTATCTGGTGG        
  ENV        Clade 1A                   TGGGAAAACAGAATGGCCCT        AAGGCCCTTGTTATGCTCCC
  Clade 1B   TCCATGGACTGACAGTGGGA       AAAGCAATTCCAGCAGCCAC        
  Clade 2    AGACCCACCAGTCAAATGGC       TTTGGTGTGATCCCACCTGG        
  Clade 3A   GCGGTAAGTCTTTGCAAGGC       CCAGAATGGCTCCAGACATGT       
  Clade 3B   CTGGACAATCAGGACCCACC       GGCCTTGCAAAGCCTTTGTT        
  MSRV       CTTCCAGAATTGAAGCTGTAAAGC   GGGTTGTGCAGTTGAGATTTCC      
  Control    RPL19                      ATGTATCACAGCCTGTACCTG       TTCTTGGTCTCTTCCTCCTTG
  RPL13      CCTGGAGGAGAAGAGGAAAGAGA    TTGAGGACCTCTGTGTATTTGTCAA   
  UBC        ATTTGGGTCGCGGTTCTTG        TGCCTTGACATTCTCGATGGT       
